Cardiff Oncology, Inc.

NasdaqCM:CRDF Rapport sur les actions

Capitalisation boursière : US$149.2m

Cardiff Oncology Croissance future

Future contrôle des critères 0/6

Les revenus et les bénéfices de Cardiff Oncology devraient diminuer respectivement de 32.6% et de 29% par an, tandis que le BPA devrait croître de diminuer de 19.8% par an.

Informations clés

-29.0%

Taux de croissance des bénéfices

-19.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices27.1%
Taux de croissance des recettes-32.6%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour06 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Oct 09
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 04

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Jun 19
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 09

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Mar 03
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Nov 16
Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28
How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24
What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:CRDF - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20260-77-62-674
12/31/20250-57-49-485
12/31/20241-47-43-385
6/30/20241-41-32-32N/A
3/31/20241-40-31-30N/A
12/31/20230-41-31-31N/A
9/30/20230-41-34-33N/A
6/30/20230-40-33-33N/A
3/31/20230-39-33-32N/A
12/31/20220-39-35-34N/A
9/30/20220-39-33-32N/A
6/30/20220-38-30-30N/A
3/31/20220-34-28-27N/A
12/31/20210-28-23-23N/A
9/30/20210-25-21-21N/A
6/30/20210-23-19-19N/A
3/31/20210-24-19-19N/A
12/31/20200-23-17-16N/A
9/30/20200-20-15-14N/A
6/30/20200-20-14-14N/A
3/31/20200-17-13-13N/A
12/31/20190-17-13-13N/A
9/30/20190-17-14-14N/A
6/30/20190-16-14-14N/A
3/31/20190-19-14-14N/A
12/31/20180-19-13-13N/A
9/30/20180-18-13-13N/A
6/30/20181-18-16-16N/A
3/31/20181-20N/A-17N/A
12/31/20171-25N/A-23N/A
9/30/20170-31N/A-29N/A
6/30/20170-37N/A-29N/A
3/31/20170-39N/A-33N/A
12/31/20160-39N/A-31N/A
9/30/20160-38N/A-29N/A
6/30/20160-31N/A-27N/A
3/31/20160-31N/A-24N/A
12/31/20150-27N/A-22N/A
9/30/20150-25N/A-19N/A
6/30/20150-27N/A-17N/A
3/31/20150-18N/A-15N/A
12/31/20140-14N/A-13N/A
9/30/20140-11N/A-11N/A
6/30/20140-10N/A-9N/A
3/31/20140-14N/A-8N/A
12/31/20130-12N/A-7N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CRDF devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CRDF devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CRDF devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Les revenus de CRDF devraient diminuer au cours des 3 prochaines années ( -32.6% par an).

Croissance élevée des revenus: Les revenus de CRDF devraient diminuer au cours des 3 prochaines années ( -32.6% par an).


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CRDF devrait être élevé dans 3 ans


Découvrir les entreprises en croissance